Di Zhu (D Zhu)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Dendritic Cells

Toll Like Receptor

Top Venues

Signal transduction and targeted therapy

Journal of experimental & clinical cancer research : CR

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Fenglian He, Zhongen Wu, Chenglong Liu, Yuanyuan Zhu, Yan Zhou, Enming Tian, Rina Rosin-Arbesfeld, Dehua Yang, Ming-Wei Wang, Di Zhu
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal transduction and targeted therapy 9 (1) (2024)
Fenglian He, Zhongen Wu, Chenglong Liu, Yuanyuan Zhu, Yan Zhou, Enming Tian, Rina Rosin-Arbesfeld, Dehua Yang, Ming-Wei Wang, Di Zhu
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal transduction and targeted therapy 9 (1) (2024)
Fenglian He, Zhongen Wu, Chenglong Liu, Yuanyuan Zhu, Yan Zhou, Enming Tian, Rina Rosin-Arbesfeld, Dehua Yang, Ming-Wei Wang, Di Zhu
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal transduction and targeted therapy 9 (1) (2024)
Li Xia, Enming Tian, Mingcheng Yu, Chenglong Liu, Lian Shen, Yafei Huang, Zhongen Wu, Jinlong Tian, Ker Yu, Yonghui Wang, Qiong Xie, Di Zhu
RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers. Journal of experimental & clinical cancer research : CR 41 (1) (2022)
Bo Hu, Mincheng Yu, Xiaolu Ma, Jia-Lei Sun, Chenglong Liu, Chunyan Wang, Suiyi Wu, Pei-Yao Fu, Zhen Yang, Yungang He, Yuanyuan Zhu, Cheng Huang, Xin-Rong Yang, Yinghong Shi, Shuangjian Qiu, Huichuan Sun, Andrew X Zhu, Jian Zhou, Yang Xu, Di Zhu, Jia Fan
IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer discovery 12 (7) (2022)
Hao Zhang, Ya Bao, Chenglong Liu, Jianqi Li, Di Zhu, Qingwei Zhang
Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors. Future medicinal chemistry 13 (10) (2021)
Xiaoshuang Wang, Mei Feng, Tengfei Xiao, Baosen Guo, Danyang Liu, Chenglong Liu, Jinpeng Pei, Qiaofeng Liu, Yi Xiao, Rina Rosin-Arbesfeld, Ying Shi, Yang Zhou, Mengxuan Yang, Yu-Xiong Feng, Yi-Zhou Jiang, Zhimin Shao, Ker Yu, Di Zhu
BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene 40 (16) (2021)
Weizhen Li, Jia-Qiang Liu, Ming Chen, Jiang Xu, Di Zhu
Circular RNA in cancer development and immune regulation. Journal of cellular and molecular medicine (2020)
M Feng, Joy Q Jin, L Xia, T Xiao, S Mei, Xiaoshuang Wang, X Huang, J Chen, Michael Liu, C Chen, S Rafi, A X Zhu, Yu-Xiong Feng, Di Zhu
Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Science advances 5 (5) (2019)